Delivery Order SPE2DR25D2104-SPE2DR26F3PFL
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for VENCLEXTA 100 mg tablets (120-count units) valued at $12,463.22 on October 30, 2025, with an ultimate completion date of November 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child order under the company's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $19,456.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp for VENCLEXTA 100 mg tablets (120-count units) on October 27, 2025, with completion targeted for November 18, 2025. This is a non-set-aside, competitively awarded contract with performance based in Conshohocken, Pennsylvania. The delivery order represents a child action under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for VENCLEXTA 100 mg tablets (120-count units) valued at $9,728.17 under a firm fixed-price contract type. The award, issued on August 7, 2025, with an ultimate completion date of August 28, 2025, represents a non-competitive, competitively awarded delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 12, 2025, for the supply of VENCLEXTA 100 mg tablets (120-count units) valued at $30,755.97 under a firm fixed-price arrangement. This non-set-aside competitive award is scheduled for completion by December 4, 2025, with performance executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for VENCLEXTA 100 mg tablets (120 count units) valued at $9,728.17, with an ultimate completion date of June 24, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The award represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Venclexta 100 mg tablets (120 count) valued at $9,728.17. This competitively awarded, firm fixed-price delivery order is set to conclude by October 21, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $4,579.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for VENCLEXTA 100 mg tablets (28-count units) on July 30, 2025, with an ultimate completion date of August 20, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. Performance of this delivery order is based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a child...
- The Defense Logistics Agency awarded a $10,251.99 delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Venclexta 100 mg tablets (120-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by November 10, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA....
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $9,728.17 by the Defense Logistics Agency (DLA) for the supply of Venclexta 100 mg tablets (120-count units), with a firm fixed price structure and an ultimate completion date of September 2, 2025. This competitively awarded, non-set-aside contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Venclexta 100 mg tablets in quantities of 120 units. This firm fixed price delivery order, valued at $58,369.02, represents a non-competitive, non-set-aside award and is scheduled for completion by August 14, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its...
- SPE2DR25D2104Indefinite Delivery Contract
- SPE2DR25D2104-SPE2DR26F3PFLDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for VENCLEXTA 100 mg tablets (120 count) on November 17, 2025, valued at $10,251.99 with firm fixed pricing and an ultimate completion date of December 9, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. VENCLEXTA, a specialty oncology medication, represents the type of brand-name pharmaceutical product the company delivers through its extensive DLA portfolio across multiple therapeutic domains. The company's demonstrated capability to fulfill federal medical supply requirements through open competition, combined with its expansive prime vendor contract, positions it as a key supplier for the Defense Health Agency and other government healthcare systems requiring reliable access to specialty medications and medical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.3k | 11/17/25 |